Madrigals Rezdiffra (resmetirom), an oral thyroid hormone receptor-beta agonist, became the first FDA-approved treatment for MASH/NASH with moderate-to-advanced fibrosis in March 2024
It works by mimicking the hormone GLP-1, which acts in the brain to reduce appetite and increase feelings of satiety, thereby promoting weight loss
Putting the numbers in context Here is a side-by-side comparison of peak weight loss results from both compounds
Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk
PlexusDx runs its own Weight Management Protocols, offering Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection and Tirzepatide Oral but it leads with the Precision Peptide Genetic Test, which reads 14 pathways, 49 peptides, 150+ genetic insights, including GLP1R, TCF7L2 and FTO
This was partly due to delayed regulatory approvals for Semaglutide in Canada, which impacted revenue